Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

First Large Study Comparing Leading Hepatitis C Therapies Provides

Important Insights to Help Guide Clinical Practice

MILAN, Italy, April 26 /PRNewswire-FirstCall/ -- Final results of the IDEAL study, the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C, were presented today at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), providing important insights that may help guide clinical practice for physicians worldwide treating this serious and potentially life-threatening disease.

The IDEAL study compared combination therapy with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) vs. Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP),(1) as well as a lower dose of PEGINTRON in an investigational combination with REBETOL. The results showed that sustained virologic response (SVR),(2) the primary endpoint of the study, was similar for all three treatment regimens. The study also showed in secondary analyses that PEGINTRON combination therapy provided greater predictability of response at important treatment milestones and significantly lower relapse rates after the end of treatment than Pegasys and Copegus combination therapy, despite patients in the Pegasys arm overall receiving a significantly higher median ribavirin dose over the duration of the study. Safety and tolerability were similar among the treatment arms.

"IDEAL provides important insights about the similarities and differences of the two leading combination therapies for hepatitis C, and how physicians can use these findings to help manage their patients," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute.

In IDEAL (Individualized Dosing Efficacy vs. flat dosing to assess optimaL pegylated interferon therapy), 3,070 previously untreated U.S. patients with HCV genotype 1, the most co
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/t63pbj/medical_device ) has announced the ... Markets Seminar" conference to their offering. ... well established, the next growth area is ... with other countries in this region have all implemented, ... medical device regulations. This seminar will provide a comprehensive ...
(Date:7/27/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... from institutional and accredited investors for a registered ... common stock and 3.35 million common stock purchase ...
(Date:7/27/2015)... , July 27, 2015  Cardica, Inc. (Nasdaq: CRDC ... its fiscal fourth quarter ended June 30, 2015, on Thursday, ... host a conference call at 4:30 p.m. Eastern Time to ... company,s business. Conference Call Details To access ... p.m. Eastern Time via phone, please dial 877-703-6106 from ...
Breaking Medicine Technology:Medical Device Regulation in Asia/Pacific Markets Seminar: London, UK - 21st, 22nd of September 2015 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2
... Candidate to Enter Clinical ... Studies in ... today it has initiated a Phase I clinical study of a ... safety, tolerability, and systemic pharmacokinetics of a topical,patch formulation of diclofenac ...
... Antisense Drug Targeting Glucagon Receptor for Treatment ... of Type 2 ... ) announced today it has earned $5,million from Ortho-McNeil, Inc. (OMI), a ... Phase 1,clinical trial of ISIS 325568. The collaboration between Isis and ...
Cached Medicine Technology:Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch 2Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch 3Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568 2Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568 3
(Date:7/27/2015)... ... 27, 2015 , ... On July 14, 2015, Harper’s Bazaar Magazine in an ... skin issues such as stretch marks , fine lines , and ... treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Eugene Batelli, D.P.M., ... accomplished athlete. “The patient is high-end athlete, whose accomplishments include running in 27 ... of Achilles tendon pain, which was diagnosed as tendinitis. I did an ultrasound ...
(Date:7/27/2015)... ... July 27, 2015 , ... The Maricopa Community Colleges today ... foster care system to get into and complete college. , The “Bridging Success ... an event today with partners from across the valley. , The initiative advisory board ...
(Date:7/27/2015)... New York, NY (PRWEB) , ... July 27, 2015 , ... ... North American tour. He will be performing for one additional night at each ... can add promo/coupon code DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America ...
(Date:7/27/2015)... , ... July 27, 2015 ... ... Global Calcium Propionate industry is a professional and in-depth research report. The ... industry chain structure, international market analysis etc. This report covers the global ...
Breaking Medicine News(10 mins):Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3
... cold virus to deliver pluripotent cells circumvents safety concerns, ... Researchers report that they have sidestepped a major technical ... adult cells. , A team of Boston scientists developed ... -- which are functionally similar to embryonic stem cells, ...
... to Eat Right, Move More and ... Milk Their Diets, NASHVILLE, Tenn., ... of different fad diets -- which seem to go in,and out of fashion ... three Americans -- including 27 percent of,Nashville residents -- remain overweight or obese., ...
... You Pink" campaign warns of "pinkwashing"., SAN ... respected watchdog of the breast cancer movement - ... Pink" campaign. The annual consumer,education campaign offers tips ... ( http://www.thinkbeforeyoupink.org ), This year,s campaign warns ...
... PHILADELPHIA, Sept. 25 The Council on Compulsive,Gambling of ... Systems Inc., and the Western Psychiatric Institute and,Clinic, our ... East Holiday Inn at 4751 Linden Road will host ... The Conference will be opened by,Tom Wolf, Secretary of ...
... 25 Sept. 26, 2008, marks the,100th anniversary ... 1908,Jersey City, N.J., was the first city in ... water. Since then, incidences of,waterborne diseases have plummeted, ... Director Gary Zimmerman,offers the following comments on behalf ...
... Employees Proves Worksite Wellness Programs Work, DALLAS, Sept. ... been recognized by the American Heart Association,s,Start! Fit-Friendly Companies ... place -- a 20 percent increase over last year., ... to get,Americans walking. Most adult Americans spend a majority ...
Cached Medicine News:Health News:Researchers Report Stem Cell Advance 2Health News:Researchers Report Stem Cell Advance 3Health News:Researchers Report Stem Cell Advance 4Health News:Message to Tennessee Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Tennessee Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Breast Cancer Action Targets Yoplait in 'Think Before You Pink' Campaign; Calls for Yogurt Without Artificial Hormones 2Health News:Statewide Gambling Conference -- Series of 'Firsts' -- Begins 9-30-08 2Health News:AWWA Marks 100th Anniversary of Chlorine Disinfection 2Health News:American Heart Association Announces Start! Fit-Friendly Companies 2Health News:American Heart Association Announces Start! Fit-Friendly Companies 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: